Algernon Pharmaceuticals Inc. (AGN.CN)
CAD 0.07
(0.0%)
CAD 0.07
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.01 Million CAD | 38.9% |
| 2022 | -6.05 Million CAD | 24.78% |
| 2021 | -8.05 Million CAD | 8.14% |
| 2020 | -8.76 Million CAD | -355.19% |
| 2019 | -1.92 Million CAD | -103.0% |
| 2018 | -948.55 Thousand CAD | 5.72% |
| 2017 | -1 Million CAD | 65.72% |
| 2016 | -2.93 Million CAD | -301.73% |
| 2015 | -730.46 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -980.36 CAD | 99.81% |
| 2024 Q1 | -521.97 Thousand CAD | 47.05% |
| 2024 Q3 | -465.66 Thousand CAD | -47399.12% |
| 2023 Q4 | -985.84 Thousand CAD | 12.6% |
| 2023 Q2 | -1.24 Million CAD | 33.64% |
| 2023 FY | -3.7 Million CAD | 38.9% |
| 2023 Q1 | -1.88 Million CAD | 15.21% |
| 2023 Q3 | -1.12 Million CAD | 9.6% |
| 2022 Q3 | -801.16 Thousand CAD | 56.35% |
| 2022 Q4 | -2.21 Million CAD | -176.8% |
| 2022 FY | -6.05 Million CAD | 24.78% |
| 2022 Q2 | -1.83 Million CAD | -52.94% |
| 2022 Q1 | -1.2 Million CAD | -400.84% |
| 2021 Q4 | -239.61 Thousand CAD | 85.67% |
| 2021 Q1 | -3.42 Million CAD | -15.42% |
| 2021 Q2 | -2.38 Million CAD | 30.5% |
| 2021 Q3 | -1.67 Million CAD | 29.84% |
| 2021 FY | -8.05 Million CAD | 8.14% |
| 2020 Q2 | -793.77 Thousand CAD | -208.6% |
| 2020 Q4 | -2.97 Million CAD | 35.2% |
| 2020 Q3 | -4.58 Million CAD | -477.4% |
| 2020 Q1 | -257.21 Thousand CAD | 40.51% |
| 2020 FY | -8.76 Million CAD | -355.19% |
| 2019 FY | -1.92 Million CAD | -103.0% |
| 2019 Q4 | -432.34 Thousand CAD | 18.85% |
| 2019 Q3 | -532.76 Thousand CAD | -19.19% |
| 2019 Q2 | -446.99 Thousand CAD | 12.94% |
| 2019 Q1 | -513.43 Thousand CAD | -164.7% |
| 2018 Q1 | -196.25 Thousand CAD | 33.29% |
| 2018 FY | -948.55 Thousand CAD | 5.72% |
| 2018 Q4 | -193.96 Thousand CAD | 51.2% |
| 2018 Q3 | -397.46 Thousand CAD | -147.08% |
| 2018 Q2 | -160.86 Thousand CAD | 18.04% |
| 2017 Q1 | -521.66 Thousand CAD | -87.56% |
| 2017 Q2 | -325.68 Thousand CAD | 37.57% |
| 2017 Q3 | -310.41 Thousand CAD | 4.69% |
| 2017 Q4 | -294.21 Thousand CAD | 5.22% |
| 2017 FY | -1 Million CAD | 65.72% |
| 2016 FY | -2.93 Million CAD | -301.73% |
| 2016 Q4 | -278.12 Thousand CAD | 41.14% |
| 2016 Q3 | -472.51 Thousand CAD | 76.65% |
| 2016 Q2 | -2.02 Million CAD | -1159.46% |
| 2016 Q1 | -160.64 Thousand CAD | 69.5% |
| 2015 FY | -730.46 Thousand CAD | 0.0% |
| 2015 Q4 | -526.67 Thousand CAD | -158.44% |
| 2015 Q3 | -203.79 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Asep Medical Holdings Inc | -7.72 Million CAD | 35.01% |
| BetterLife Pharma Inc. | -3.24 Million CAD | -54.867% |
| BioVaxys Technology Corp. | -2.4 Million CAD | -108.859% |
| ChitogenX Inc. | -2.83 Million CAD | -77.316% |
| Rapid Dose Therapeutics Corp. | -3.73 Million CAD | -34.216% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 60.35% |
| Entheon Biomedical Corp. | -313.99 Thousand CAD | -1498.147% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 1.334% |
| Glow Lifetech Corp. | -1.64 Million CAD | -205.474% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | -643.726% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | -557.717% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | -1228.818% |
| MYND Life Sciences Inc. | -1.8 Million CAD | -177.582% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -317.372% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | -64.846% |
| PreveCeutical Medical Inc. | -963.12 Thousand CAD | -421.019% |
| Telescope Innovations Corp. | -5.76 Million CAD | 12.983% |